Literature DB >> 22102174

The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer.

LingLing Pan1, JingYi Cheng, Min Zhou, ZhiFeng Yao, YingJian Zhang.   

Abstract

OBJECTIVE: The aim of the present study was to investigate the prognostic significance of FDG uptake measured as maximum standardized uptake value (SUVmax) in primary tumor by positron emission tomography with fluorine-18-fluorodeoxyglucose (FDG-PET/CT) and pretreatment serum squamous cell carcinoma antigen (SCC-ag) in patients with cervical cancer.
METHODS: 82 consecutive patients with biopsy-proven cervical cancer who had PET/CT before any treatment were enrolled in this study. The SUVmax of the primary cervical tumor mass was obtained and compared with pretreatment SCC-ag and pathological prognostic factors after the initial treatment.
RESULTS: There was significant correlation between the SUVmax of the primary tumor and tumor maximum size (p = 0.0024). The serum SCC-ag had a statistically significant association with lymph node metastasis (p = 0.0373), although there was no correlation between the SUVmax of the primary tumor and the serum SCC-ag (r (2) = -0.57). The higher SUVmax of primary tumor (≥11.2) plus pelvic lymph node (PLN) metastasis and higher SUVmax plus higher serum SCC-ag (≥6.4 ng/nl) were two most significant variables that predicted worse prognosis (p = 0.0099 and p = 0.0020, respectively).
CONCLUSIONS: Higher pretreatment SUVmax of primary tumor indicated worse prognosis, and the prognosis of patients with higher pretreatment SUVmax plus PLN metastasis was even worse both in patients of squamous cell carcinoma (SCC) and non-SCC of cervix. As for patients with SCC of cervix, higher pretreatment serum SCC-ag not only predicted worse prognosis but also predicted disease recurrence in the posttreatment surveillance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102174     DOI: 10.1007/s00432-011-1092-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  50 in total

1.  Molecular imaging in cancer.

Authors:  Ralph Weissleder
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

2.  FDG-PET for management of cervical and ovarian cancer.

Authors:  Laura J Havrilesky; Shalini L Kulasingam; David B Matchar; Evan R Myers
Journal:  Gynecol Oncol       Date:  2005-04       Impact factor: 5.482

3.  The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix.

Authors:  Keiichiro Nakamura; Yoshihiro Okumura; Junichi Kodama; Atsushi Hongo; Susumu Kanazawa; Yuji Hiramatsu
Journal:  Gynecol Oncol       Date:  2010-06-26       Impact factor: 5.482

4.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.

Authors:  P W Grigsby; B A Siegel; F Dehdashti
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

5.  Placental site trophoblastic tumor: immunohistochemical and nuclear DNA study.

Authors:  M Kashimura; Y Kashimura; K Oikawa; C Sakamoto; Y Matsuura; S Nakamura
Journal:  Gynecol Oncol       Date:  1990-08       Impact factor: 5.482

6.  Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

7.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.

Authors:  Robert J Downey; Timothy Akhurst; Mithat Gonen; Alain Vincent; Manjit S Bains; Steven Larson; Valerie Rusch
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

Review 8.  Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.

Authors:  LingLing Pan; Ping Gu; Gang Huang; HuiPing Xue; ShuQi Wu
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-09       Impact factor: 2.566

9.  Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.

Authors:  Julie K Schwarz; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  JAMA       Date:  2007-11-21       Impact factor: 56.272

Review 10.  Novel imaging techniques as response biomarkers in cervical cancer.

Authors:  Vanessa N Harry
Journal:  Gynecol Oncol       Date:  2010-02       Impact factor: 5.482

View more
  11 in total

1.  Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy.

Authors:  Shigetaka Yagi; Tamaki Yahata; Yasushi Mabuchi; Yuko Tanizaki; Aya Kobayashi; Michihisa Shiro; Nami Ota; Sawako Minami; Masaki Terada; Kazuhiko Ino
Journal:  Mol Clin Oncol       Date:  2016-07-07

2.  A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer.

Authors:  Antoine Schernberg; Sylvain Reuze; Fanny Orlhac; Irène Buvat; Laurent Dercle; Roger Sun; Elaine Limkin; Alexandre Escande; Christine Haie-Meder; Eric Deutsch; Cyrus Chargari; Charlotte Robert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-15       Impact factor: 9.236

3.  Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?

Authors:  Marie Voglimacci; Erwan Gabiache; Amélie Lusque; Gwenaël Ferron; Anne Ducassou; Denis Querleu; Stéphanie Motton; Elodie Chantalat; Frédéric Courbon; Alejandra Martinez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-07       Impact factor: 9.236

4.  Prognostic value of 18F-FDG PET/CT and MRI features in patients with high-risk and very-high-risk cutaneous squamous cell carcinoma.

Authors:  Masaya Kawaguchi; Hiroki Kato; Kanako Matsuyama; Yoshifumi Noda; Fuminori Hyodo; Masayuki Matsuo
Journal:  Br J Radiol       Date:  2022-01-07       Impact factor: 3.629

Review 5.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

6.  Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational 18F-FDG PET/CT study.

Authors:  Siyao Du; Hongzan Sun; Si Gao; Jun Xin; Zaiming Lu
Journal:  Quant Imaging Med Surg       Date:  2019-03

Review 7.  Functional imaging to predict tumor response in locally advanced cervical cancer.

Authors:  Tara D Barwick; Alexandra Taylor; Andrea Rockall
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 8.  The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review.

Authors:  Ziqi Zhou; Wenbo Li; Fuquan Zhang; Ke Hu
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240

9.  Relationship of EGFR Mutation to Glucose Metabolic Activity and Asphericity of Metabolic Tumor Volume in Lung Adenocarcinoma.

Authors:  Wonseok Whi; Seunggyun Ha; Sungwoo Bae; Hongyoon Choi; Jin Chul Paeng; Gi Jeong Cheon; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-06-14

10.  Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.

Authors:  Jin Hwa Hong; Kyung Jin Min; Jae Kwan Lee; Kyeong A So; Un Suk Jung; Sungeun Kim; Jae Seon Eo
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.